Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Elicio Therapeutics (ELTX) Equity Income (2020 - 2022)

Elicio Therapeutics filings provide 3 years of Equity Income readings, the most recent being $9000.0 for Q3 2022.

  • On a quarterly basis, Equity Income fell 70.97% to $9000.0 in Q3 2022 year-over-year; TTM through Mar 2023 was $142000.0, a 192.21% increase, with the full-year FY2022 number at $151000.0, up 257.29% from a year prior.
  • Equity Income hit $9000.0 in Q3 2022 for Elicio Therapeutics, down from $133000.0 in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $133000.0 in Q2 2022 to a low of -$172000.0 in Q4 2021.
  • Median Equity Income over the past 3 years was $18500.0 (2020), compared with a mean of -$1600.0.
  • Biggest five-year swings in Equity Income: tumbled 178.57% in 2021 and later soared 704.55% in 2022.
  • Elicio Therapeutics' Equity Income stood at -$127000.0 in 2020, then tumbled by 35.43% to -$172000.0 in 2021, then soared by 105.23% to $9000.0 in 2022.
  • The last three reported values for Equity Income were $9000.0 (Q3 2022), $133000.0 (Q2 2022), and $9000.0 (Q1 2022) per Business Quant data.